Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,978 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials.
Yukami H, Kawazoe A, Lin YT, Koyama S, Fukuoka S, Hara H, Takahashi N, Kojima T, Asayama M, Yoshii T, Bando H, Kotani D, Nakamura Y, Kuboki Y, Mishima S, Wakabayashi M, Kuwata T, Goto M, Higuchi K, Yoshino T, Doi T, Nishikawa H, Shitara K. Yukami H, et al. Among authors: koyama s. Clin Cancer Res. 2022 Aug 15;28(16):3480-3488. doi: 10.1158/1078-0432.CCR-22-0630. Clin Cancer Res. 2022. PMID: 35679062 Free PMC article.
Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S, Masuhiro K, Yaga M, Iwahori K, Takeda Y, Kida H, Kumanogoh A. Shiroyama T, et al. Among authors: koyama s. Sci Rep. 2019 Feb 21;9(1):2447. doi: 10.1038/s41598-019-39120-6. Sci Rep. 2019. PMID: 30792455 Free PMC article.
Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report.
Matsumoto K, Shiroyama T, Hashida N, Miyake K, Yamamoto Y, Kuge T, Yoneda M, Yamamoto M, Naito Y, Suga Y, Fukushima K, Koyama S, Iwahori K, Hirata H, Nagatomo I, Takeda Y, Kumanogoh A. Matsumoto K, et al. Among authors: koyama s. Angiogenesis. 2022 May;25(2):147-149. doi: 10.1007/s10456-021-09820-7. Epub 2021 Sep 30. Angiogenesis. 2022. PMID: 34591203
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
Kawazoe A, Itahashi K, Yamamoto N, Kotani D, Kuboki Y, Taniguchi H, Harano K, Naito Y, Suzuki M, Fukutani M, Higuchi T, Ikeno T, Wakabayashi M, Sato A, Koyama S, Nishikawa H, Shitara K. Kawazoe A, et al. Among authors: koyama s. Clin Cancer Res. 2021 Dec 15;27(24):6709-6715. doi: 10.1158/1078-0432.CCR-21-1929. Epub 2021 Sep 30. Clin Cancer Res. 2021. PMID: 34593531 Clinical Trial.
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H. Takeuchi Y, et al. Among authors: koyama s. Sci Immunol. 2021 Nov 12;6(65):eabc6424. doi: 10.1126/sciimmunol.abc6424. Epub 2021 Nov 12. Sci Immunol. 2021. PMID: 34767457
Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Matsumoto K, Shiroyama T, Kuge T, Miyake K, Yamamoto Y, Yoneda M, Yamamoto M, Naito Y, Suga Y, Fukushima K, Koyama S, Iwahori K, Hirata H, Nagatomo I, Takeda Y, Kumanogoh A. Matsumoto K, et al. Among authors: koyama s. Lung Cancer. 2021 Dec;162:175-184. doi: 10.1016/j.lungcan.2021.11.008. Epub 2021 Nov 17. Lung Cancer. 2021. PMID: 34823108
Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer.
Aokage K, Tsuboi M, Zenke Y, Horinouchi H, Nakamura N, Ishikura S, Nishikawa H, Kumagai S, Koyama S, Kanato K, Kataoka T, Wakabayashi M, Fukutani M, Fukuda H, Ohe Y, Watanabe SI; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group. Aokage K, et al. Among authors: koyama s. Jpn J Clin Oncol. 2022 Apr 6;52(4):383-387. doi: 10.1093/jjco/hyab208. Jpn J Clin Oncol. 2022. PMID: 34999817 Free PMC article.
1,978 results